Fontconfig warning: ignoring C.UTF-8: not a valid language tag
Sevelamer (rINN) (/sɛˈvɛləmər/ or /sɛˈvɛləmɪər/) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is currently marketed by Allianze Med Pharma under the trade name [Renavel] available in 400mg and 800mg and Sanofi under the trade names Renagel available in 800mg. (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
